Screener
Vir Biotechnology, Inc. VIR Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $287.6M-6.1% | $283.04M-23.1% | $241.07M-24.4% | $179.26M-32.2% | $306.28M-3.4% | ||
| $249.86M-35.5% | $196.28M-62.1% | $228.75M-66.3% | $327.75M-55.7% | $387.65M-54.4% | ||
| $573.74M-22.0% | $522.99M-43.9% | $514.08M-50.7% | $545.68M-47.9% | $735.71M-39.0% | ||
| $50.43M-17.0% | $53.16M-13.8% | $55.62M-12.0% | $58.2M-10.2% | $60.8M-8.0% | ||
| $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | $16.94M0.0% | ||
| $7.7M-3.7% | $7.78M-3.7% | $7.85M-3.3% | $7.92M-58.9% | $8M-57.7% | ||
| $1.21B+1.9% | $1.03B-21.6% | $1B-28.3% | $1.02B-32.0% | $1.19B-28.6% | ||
| $17.75M+45.1% | $5.45M+46.2% | $9.8M+92.9% | $6.85M-6.3% | $12.23M+179% | ||
| $94.96M-9.6% | $73.56M-46.4% | $92.82M-22.4% | $75.22M-35.8% | $105M+8.9% | ||
| $232.31M-5.2% | $212.82M-19.4% | $237.55M-4.4% | $223.36M-13.3% | $245.06M+3.9% | ||
| 300M0.0% | 300M0.0% | 300M+2,142,757% | 300M0.0% | 300M0.0% | ||
| -$1.24B-25.4% | -$1.32B-50.3% | -$1.2B-57.6% | -$1.15B-76.3% | -$991.71M-125% | ||
| $982.49M+3.7% | $812.77M-22.1% | $765.28M-33.5% | $796.1M-35.8% | $947.47M-33.9% | ||
| $1.21B+1.9% | $1.03B-21.6% | $1B-28.3% | $1.02B-32.0% | $1.19B-28.6% |
FAQ
- What are Vir Biotechnology, Inc.'s total assets?
- Vir Biotechnology, Inc. (VIR) holds $1.2B in total assets, up 1.9% year over year.
- How much debt does Vir Biotechnology, Inc. have?
- Vir Biotechnology, Inc. carries $93.3M in total debt against $982.5M of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Vir Biotechnology, Inc. have?
- Vir Biotechnology, Inc. holds $287.6M in cash and equivalents.
- Can Vir Biotechnology, Inc. cover its short-term obligations?
- Its current ratio is 6.04 — current assets exceed current liabilities.
- Where does Vir Biotechnology, Inc.'s balance sheet data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
